Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric α-fetoprotein promoter

Cancer Letters

Volumn 264, Issue 1, 2008, Pages 71-82

  Cai, Xiaokun ^a   Zhou, Junli ^a   Chang, Ying ^a   Sun, Xuemei ^a   Li, Peiyuan ^a   Lin, Junsheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chimeric fetoprotein (AFP) promoter; Hepatocarcinoma (HCC); Hypoxia; Purine nucleoside phosphorylase (PNP) suicide gene; Targeting gene therapy

Indexed keywords

6 METHYLPURINE; 9 (2 DEOXY BETA DEXTRO RIBOFURANOSYL) 6 METHYLPURINE; ALPHA FETOPROTEIN; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER GENE THERAPY; CYTOTOXICITY; ESCHERICHIA COLI; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; LIVER CELL CARCINOMA; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE THERAPY;

ALPHA-FETOPROTEINS; APOPTOSIS; BYSTANDER EFFECT; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; ESCHERICHIA COLI; GENE TARGETING; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HELA CELLS; HUMANS; LIVER NEOPLASMS; PLASMIDS; PROMOTER REGIONS (GENETICS); PURINE-NUCLEOSIDE PHOSPHORYLASE; RECOMBINANT PROTEINS; RNA, MESSENGER;

ESCHERICHIA COLI;

EID: 42649141632     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.027     Document Type: Article

References (20)

1. Friedlos F., Davies L., Scanlon I., Ogilvie L.M., Martin J., Stribbling S.M., Spooner R.A., Niculescu-Duvaz I., Marais R., and Springer C.J. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 62 (2002) 1724-1729
2. Galanis E., Vile R., and Russell S.J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38 (2001) 177-192
3. Schatzlein A.G. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs 12 (2001) 275-304
4. Xu L., Frederik P., Pirollo K.F., Tang W.H., Rait A., Xiang L.M., Huang W., Cruz I., Yin Y., and Chang E.H. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum. Gene Ther. 13 (2002) 469-481
5. Denny W.A. Pro-drugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotechnol. 2003 (2003) 48-70
6. Cao G., Kuriyama S., Gao J., Kikukawa M., Cui L., Nakatani T., Zhang X., Tsujinoue H., Pan X., Fukui H., and Qi Z. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther. 6 (1999) 83-90
7. Gerolami R., Cardoso J., Lewin M., Bralet M.P., Sa Cunha A., Clement O., Brechot C., and Tran P.L. Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res. 60 (2000) 993-1001
8. Kanai F., Shiratori Y., Yoshida Y., Wakimoto H., Hamada H., Kanegae Y., Saito I., Nakabayashi H., Tamaoki T., Tanaka T., Lan K.H., Kato N., Shiina S., and Omata M. Gene therapy for alpha-fetoprotein-producing human HCC cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 23 (1996) 1359-1368
9. Ido A., Uto H., Moriuchi A., Nagata K., Onaga Y., Onaga M., Hori T., Hirono S., Hayashi K., Tamaoki T., and Tsubouchi H. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 61 (2001) 3016-3021
10. Nakabayashi H., Hashimoto T., Miyao Y., Tjong K.K., Chan J., and Tamaoki T. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human HCC. Mol. Cell. Biol. 11 (1991) 5885-5893
11. Sorscher E.J., Peng S., Bebok Z., Allan P.W., Bennett Jr. L.L., and Parker W.B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1 (1994) 233-238
12. Zhang Y., Parker W.B., Sorscher E.J., and Ealick S.E. PNP anticancer gene therapy. Curr. Top. Med. Chem. 5 (2005) 1259-1274
13. Silamkoti A.V., Allan P.W., Hassan A.E., Fowler A.T., Sorscher E.J., Parker W.B., and Secrist III J.A. Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer. Nucleosides Nucleotides Nucleic Acids 24 (2005) 881-885
14. Parker W.B., Allan P.W., Shaddix S.C., Rose L.M., Speegle H.F., Gillespie G.Y., and Bennett Jr. L.L. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 55 (1998) 1673-1681
15. Hughes B.W., King S.A., Allan P.W., Parker W.B., and Sorscher E.J. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J. Biol. Chem. 273 (1998) 2322-2328
16. Lockett L.J., Molloy P.L., Russell P.J., and Both G.W. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer Res. 3 (1997) 2075-2080
17. Krohne T.U., Shankara S., Geissler M., Roberts B.L., Wands J.R., Blum H.E., and Mohr L. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34 (2001) 511-518
18. Hughes B.W., Wells A.H., Bebok Z., Gadi Jr. V.K., Garver R.I., Parker W.B., and Sorscher E.J. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55 (1995) 3339-3345
19. Gadi V.K., Alexander S.D., Kudlow J.E., Allan P., Parker W.B., and Sorscher E.J. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 7 (2000) 1738-1743
20. Gadi V.K., Alexander S.D., Waud W.R., Allan P.W., Parker W.B., and Sorscher E.J. A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 304 (2003) 1280-1284